anti-CD3/undisclosed target bispecific T-cell engager (Micromet)

N/A

Report date: 2026/03/19 16:58:18

Base Information

Drug Nameanti-CD3/undisclosed target bispecific T-cell engager (Micromet)
Drug Alias NameBiTE antibodies (Amgen/MD Anderson Cancer Center)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionT cell surface glycoprotein CD3 modulators
TargetsT cell surface glycoprotein CD3
Therapy Area/IndicationsMyelodysplastic Syndromes
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAmgen Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesThe University Of Texas MD Anderson Cancer CenterAmgen Inc
Active IndicationsN/A
Inactive IndicationsMyelodysplastic Syndromes

Other Information

ATC CodeN/A
Related LinksN/A